(ACIU) AC Immune S.A. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ACIU) AC Immune S.A. Complete Analysis Pack
Download Your Competitive Advantage
This AC Immune S.A. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy and shows how these choices support positioning and sales. The page contains a real preview/sample of the report so you can review style and content; purchase the full version to download the complete ready-to-use analysis.
Product
Clinical-stage neurodegeneration pipeline
AC Immune S.A.’s clinical-stage neurodegeneration pipeline targets protein-misfolding diseases, especially Alzheimer’s disease, where about 55 million people live with dementia worldwide. Its SupraAntigen and Morphomer platforms support vaccines, antibodies, and small molecules, giving the Company multiple shots at both treatment and diagnosis. This product set is built for a high-need market with no cure and huge unmet demand.
Crenezumab Phase II
Crenezumab Phase II is a humanized, conformation-specific monoclonal antibody in AC Immune S.A.’s Alzheimer’s prevention program, targeting amyloid-beta pathology. Alzheimer’s affects about 55 million people worldwide, so the unmet need is large. In the 4P mix, this asset strengthens Product differentiation through a precision immunotherapy platform and a clear disease-modifying thesis.
ACI-24 anti-Abeta vaccine
ACI-24 is AC Immune S.A.’s anti-Abeta vaccine candidate, positioned in the product mix as a differentiated Alzheimer’s disease therapy. It is in Phase II clinical evaluation for Alzheimer’s disease, after completing a Phase Ib study in Down syndrome, giving the program human data across 2 patient groups. That clinical breadth supports its product value and long-term partnering appeal.
ACI-35 anti-Tau vaccine
ACI-35 is AC Immune S.A.’s anti-Tau vaccine candidate for Alzheimer’s disease. It completed Phase Ib, which means the program has already shown early human safety and immune-response data. The asset fits AC Immune S.A.’s broader Tau-targeting plan, a key part of its neurodegeneration pipeline.
- Anti-Tau vaccine candidate
- Completed Phase Ib
- Supports Tau strategy
Tau PET tracer and small molecules
AC Immune's Tau PET tracer is in Phase II, giving the Company a sharper diagnostic tool for tau pathology, while small-molecule inhibitors aim to stop tau aggregation at the source.
The pipeline also reaches beyond tau, with early-stage programs for TDP-43, alpha-synuclein, and NLRP3, broadening its neurodegeneration platform.
- Phase II Tau PET tracer
- Small molecules block tau aggregation
- Targets: TDP-43, alpha-synuclein, NLRP3
AC Immune Targets Alzheimer’s From Treatment to Detection
AC Immune S.A.’s Product mix centers on late-stage Alzheimer’s and tau assets, led by crenezumab, ACI-24, and ACI-35, plus a Phase II tau PET tracer. The portfolio spans immunotherapy and diagnostics, so the Company can attack both disease biology and detection. With about 55 million people living with dementia worldwide, the addressable need is huge.
| Asset | Stage | Role |
|---|---|---|
| Crenezumab | Phase II | Abeta antibody |
| ACI-24 | Phase II | Abeta vaccine |
| Tau PET tracer | Phase II | Diagnostic |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P analysis of AC Immune S.A.'s product, pricing, place, and promotion strategy.
Editable Excel File
Distills AC Immune S.A.’s 4Ps into a quick, structured snapshot that relieves research overload and speeds decision-making.
Reference Sources
Cites primary industry reports, clinical registries, and peer-reviewed studies to validate assumptions and speed investor due diligence.
Place
Lausanne headquarters
AC Immune S.A.'s Lausanne headquarters anchors its biotech R&D work in Switzerland, with discovery, clinical development, and partnership management all run from this base. Lausanne also links the Company to the Lake Geneva life-science cluster, supporting access to talent and research partners. As a lean R&D hub, the site is built to move programs from discovery into the clinic and into strategic deals.
Clinical trial networks
AC Immune S.A. runs its pipeline through multi-site Phase Ib and Phase II trials, so access to specialist memory clinics and biomarker-rich patient pools is key. In FY2025, its development work still depended on external research centers across Europe and the U.S. to move candidates through study readouts. This place drives faster enrollment, cleaner data, and better trial quality.
Global partnership footprint
AC Immune’s global partnership footprint spans Genentech, Biogen, Janssen, Life Molecular Imaging, Eli Lilly, and WuXi Biologics, giving the Swiss company reach far beyond its home market. These 6 partners support development, manufacturing, imaging, and partnering across the value chain, which helps spread risk and speed execution. In practice, that network turns AC Immune from a single-country biotech into a cross-border platform.
Research and preclinical operations
AC Immune S.A.’s Place is centered on research and preclinical work, not retail. Its pipeline spans multiple neurodegenerative targets, including Alzheimer’s disease and NeuroOrphan indications, so activity stays in labs, clinical sites, and partner facilities.
The model fits a small, science-led footprint: discovery and preclinical programs advance through collaborations and external trial networks. That keeps access close to specialist R&D hubs and away from consumer channels.
- Labs drive discovery and preclinical testing
- Clinical sites support partner-led studies
- Alzheimer’s and NeuroOrphan targets dominate
- No retail distribution channel is used
No commercial distribution
AC Immune S.A. has no consumer sales channel: its candidates are not sold in pharmacies or online, and access runs through clinical trials, licensing, and collaboration deals. In FY2025, that means the company’s value capture stays upstream in R&D, not retail distribution.
- Clinical-trial access only
- No pharmacy or online sales
- Revenue tied to partners
AC Immune’s Lausanne HQ Drives Partner-Led Clinical Development
AC Immune S.A.'s Place is a Switzerland-based, R&D-led model centered in Lausanne, with no retail sales channel. In FY2025, its 6 partners and external trial sites across Europe and the U.S. kept development tied to specialist clinics, labs, and collaboration hubs. That setup supports faster enrollment and partner-led execution.
| Place metric | FY2025 |
|---|---|
| HQ | Lausanne, Switzerland |
| Partners | 6 |
| Channel | Clinical trials only |
What You See Is What You Get
AC Immune S.A. Reference Sources
The preview shown here is the exact, full AC Immune S.A. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no demo, no excerpts, fully editable and ready to use.
Promotion
Scientific collaboration model
AC Immune S.A. uses a scientific collaboration model, so promotion comes from co-development and validation with large biopharma partners rather than mass marketing. In 2025, this matters even more because the company is still clinical-stage and has no marketed products, so partner backing helps de-risk its pipeline and signal credibility. It has worked with names like Takeda and Eli Lilly to advance programs and share development costs.
Clinical data disclosure
AC Immune S.A. uses clinical data disclosure as a core promotion tool, sharing Phase Ib and Phase II updates to keep its pipeline visible. Trial milestones and study readouts help signal scientific progress, which matters to investors, partners, and the research community. This is especially important in a field where Phase II data often drives the next funding or licensing step.
Investor relations communications
AC Immune S.A. uses investor relations as a core promotion channel, through corporate presentations, annual reports, and shareholder updates that track pipeline progress, platform science, and strategy. Because revenue is still partnership-driven and the company reported no product sales, these communications matter more than consumer marketing. They help investors follow financing, clinical milestones, and deal activity in real time.
Scientific conferences and publications
AC Immune S.A. uses peer-reviewed publications and high-visibility conference talks to build trust in its neuroscience pipeline. This is a core biotech promotion channel: it keeps neurologists, researchers, and pharma partners close to the data, not just the brand. In 2025, that science-led message stayed central to awareness across Alzheimer’s and other neurodegeneration programs.
- Builds credibility with data first
- Raises visibility at key congresses
- Supports partner and KOL outreach
Partnership and licensing announcements
AC Immune S.A. uses partnership and licensing announcements to show platform credibility: Genentech, Biogen, Janssen, Life Molecular Imaging, Eli Lilly, and WuXi Biologics give it 6 named external allies. That mix signals third-party validation of its neurodegeneration science and helps frame the Company Name as a collaborator, not just a standalone drug maker.
- 6 alliance names
- External platform validation
- Stronger R&D partner image
AC Immune Bets on Data, Not Ads, to Win Partner Trust
AC Immune S.A. promotes through partner validation, not consumer ads: in 2025 it had 6 named alliance partners and no product sales, so every data readout and deal update matters. Conference talks, peer-reviewed papers, and investor decks are its main reach tools. That science-first promotion helps build trust with pharma, KOLs, and investors.
| Promo channel | 2025 signal |
|---|---|
| Partners | 6 named allies |
| Sales | 0 product sales |
| Core message | Clinical data |
Price
No marketed product price
AC Immune S.A. has 0 approved commercial products, so there is no retail list price for its pipeline assets. Pricing is not set at the consumer level; it will only be defined if a program reaches approval and reimbursement. In 2025/2026, the company remained a pure R&D group, so price data is still tied to development milestones, not sales.
Partner-funded economics
AC Immune S.A. creates much of its price value through partner-funded economics, which is standard for a clinical-stage biotech. Upfront fees, research funding, milestone cash, and future royalties help fund R&D while limiting direct spend. This model keeps the upside tied to pipeline progress and deal execution.
Clinical development investment
AC Immune S.A. prices clinical development as an investment, not a product margin; value is driven by R&D spend and years of testing before any sales. Asset value can rerate fast when phase data improve or when a partner adds cash and development support, so the key metric is enterprise value, not unit price. For clinical-stage biotech, one clean data readout can matter more than a full quarter of revenue.
Diagnostic and therapeutic differentiation
AC Immune’s price is set by value, not unit cost: 5 target families, Tau, Abeta, alpha-synuclein, TDP-43, and NLRP3, aim at diseases with huge unmet need. Alzheimer’s hits about 55 million people worldwide, and Parkinson’s nearly 10 million, so a clear diagnostic-therapeutic split can lift licensing terms and milestone value.
- 5 high-value target families
- 55 million dementia cases
- Nearly 10 million Parkinson’s cases
- Stronger differentiation raises licensing power
Access through trials and deals
Patients do not buy AC Immune S.A. products directly; access comes through trials, licensing, and partner-led launches, so price is set in deals, not on a shelf. In 2025, AC Immune S.A. still had no commercial product revenue, which keeps pricing tied to upfront fees, milestones, and future royalties.
Price is a BD lever, not a retail tag.
Clinical access lowers patient payment barriers.
Partner terms drive future value capture.
AC Immune’s Value Hinges on Trial Data, Not Product Sales
AC Immune S.A. has no approved products, so there is no shelf price in 2025/2026; price is set in partner deals, milestones, and future royalties. Its value is tied to clinical progress, not unit sales, with 0 commercial product revenue. Stronger data can reprice the company fast.
| Metric | 2025/2026 |
|---|---|
| Approved products | 0 |
| Commercial product revenue | 0 |
| Price driver | Partner deals |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.